A. Pataer

发表

Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.

S. Swisher, J. Heymach, D. Gibbons, 2021, Lung cancer.

Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy.

J. Roth, S. Swisher, J. Heymach, 2020, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Histopathologic Response Criteria Predict Survival of Patients with Resected Lung Cancer After Neoadjuvant Chemotherapy

Ara A Vaporciyan, Stephen G Swisher, J Jack Lee, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC).

J. Lee, S. Swisher, J. Heymach, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Effect of neoadjuvant chemotherapy on the immune microenvironment in non–small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches

Boris Sepesi, Ignacio I. Wistuba, John V. Heymach, 2018, Journal of Immunotherapy for Cancer.

Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.

Edward S. Kim, Diane D. Liu, I. Wistuba, 2017, The Annals of thoracic surgery.

Prognostic Significance of Combinations of RNA-Dependent Protein Kinase and EphA2 Biomarkers for NSCLC

J. Roth, I. Wistuba, S. Swisher, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Glutathione reductase (GSR) gene deletion and chromosome 8 aneuploidy in primary lung cancers detected by fluorescence in situ hybridization.

J. Roth, S. Swisher, R. Mehran, 2019, American journal of cancer research.

Accumulation of RNA-dependent protein kinase (PKR) in the nuclei of lung cancer cells mediates radiation resistance

S. Swisher, B. Fang, R. Shao, 2016, Oncotarget.

Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.

J. Roth, I. Wistuba, J. Lee, 2020, Clinical lung cancer.

Recent developments regarding the use of thieno[2,3-d]pyrimidin-4-one derivatives in medicinal chemistry, with a focus on their synthesis and anticancer properties.

H. Aisa, A. Pataer, Jiangyu Zhao, 2015, European journal of medicinal chemistry.

Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

N. Ajami, J. Roth, I. Wistuba, 2021, Nature Medicine.

KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations.

Jeffrey S. Morris, Jing Wang, J. Minna, 2020, American journal of cancer research.

Major Pathologic Response and Prognostic Score Predict Survival in Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy

S. Swisher, J. Heymach, A. Vaporciyan, 2022, JTO clinical and research reports.

RNA-dependent protein kinase (PKR) depletes nutrients, inducing phosphorylation of AMP-activated kinase in lung cancer

J. Roth, I. Wistuba, S. Swisher, 2015, Oncotarget.

Insulin-Like Growth Factor Binding Protein-2 Level Is Increased in Blood of Lung Cancer Patients and Associated with Poor Survival

Xifeng Wu, J. Roth, S. Swisher, 2013, PloS one.

Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.

Milind B. Suraokar, K. Coombes, B. Garcia, 2017, Cell reports.

EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer.

B. Arun, B. Ozpolat, C. Albarracin, 2019, Nanomedicine.

Tumor characteristics associated with engraftment of patient‐derived non–small cell lung cancer xenografts in immunocompromised mice

J. Roth, S. Swisher, J. Fujimoto, 2019, Cancer.

Gene mutations in primary tumors and corresponding patient-derived xenografts derived from non-small cell lung cancer.

K. Shaw, J. Roth, S. Swisher, 2015, Cancer letters.

Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.

M. Kris, V. Rusch, W. Travis, 2014, The Lancet. Oncology.

Aberrant Expression of Proteins Involved in Signal Transduction and DNA Repair Pathways in Lung Cancer and Their Association with Clinical Parameters

Jing Wang, Li Wang, J. Roth, 2012, PloS one.

Patient-derived tumor immune microenvironments in patient-derived xenografts of lung cancer

J. Roth, S. Swisher, B. Fang, 2018, Journal of Translational Medicine.

Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.

B. Ozpolat, R. Bayraktar, E. Bayraktar, 2018, Lung cancer.

Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer

N. Ajami, I. Wistuba, J. Lee, 2021, Nature Communications.

277 Combined neoadjuvant chemo-immunotherapy therapy achieves superior downstaging of resectable non-small cell lung cancer as compared to chemotherapy, mono or dual immunotherapy

J. Roth, S. Swisher, A. Tsao, 2020, Journal for ImmunoTherapy of Cancer.

Evaluation of Pathologic Response in Lymph Nodes of Lung Cancer Patients Receiving Neoadjuvant Chemotherapy.

I. Wistuba, S. Swisher, A. Vaporciyan, 2021, Journal of Thoracic Oncology.

The Role of PKR/eIF2α Signaling Pathway in Prognosis of Non-Small Cell Lung Cancer

Ignacio I. Wistuba, Liping Yu, Yihong Zhou, 2011, PloS one.

Computed Tomography RECIST Assessment of Histopathologic Response and Prediction of Survival in Patients with Resectable Non–Small-Cell Lung Cancer after Neoadjuvant Chemotherapy

Edward S. Kim, R. Munden, I. Wistuba, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC.

I. Wistuba, J. Lee, S. Swisher, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells

Jing Wang, J. Roth, I. Wistuba, 2019, Oncogene.

Epstein Barr virus–positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo

Michael L. Wang, Jing Wang, J. Roth, 2021, Blood advances.

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

N. Ajami, Jing Wang, I. Wistuba, 2023, Nature Medicine.

Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study.

J. Lee, S. Swisher, A. Tsao, 2021 .

Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy

J. Roth, I. Wistuba, S. Swisher, 2018, Cancer medicine.